Prostate cancer screening in the UK: what the 2026 decision means

For years, people have asked why the UK has no prostate cancer screening programme. In 2026 that changed, but only for a small group of men. If you have seen the headlines and wondered whether you will be invited, or whether a prostate MRI scan is now a screening test, this guide explains what was decided, who it covers and what it means for everyone else. The details are correct as of October 2026.

The short answer

• There is still no screening programme for all men in the UK.
• A targeted programme has been recommended for men aged 45 to 61 who carry a harmful BRCA2 gene variant and have a family history of certain cancers.
• In England, the government has accepted this, and the programme is expected to start rolling out in 2027.
• The screening test is a PSA blood test. MRI is used afterwards, if the PSA result is raised.
• Any man can still talk to a GP about a PSA test.

What the UK National Screening Committee decided

The UK National Screening Committee (UK NSC) advises the NHS and governments in all four UK nations on screening. In November 2025 it published a draft recommendation and held a 12-week public consultation. It received nearly 1,000 responses, most of them from members of the public.

At its meeting in March 2026, the committee agreed its final recommendation on prostate cancer screening. Its published recommendation says it:

• does not recommend population screening for prostate cancer;
• recommends a targeted programme of PSA testing every 2 years for men aged 45 to 61 who have a harmful (pathogenic) BRCA2 variant and a family history of breast, ovarian, pancreatic or prostate cancer;
• does not recommend targeted screening for any other risk group, for now.

The draft had also included men with BRCA1 variants. They were removed from the final version after advice from genetics experts, who concluded that BRCA1 carriers are not at a high enough risk.

What happens next in England

On 2 June 2026 the government accepted the recommendation for England and said the targeted programme is expected to be rolling out in 2027. According to the government's equality impact assessment, the number of eligible men is small, so the effect on NHS capacity is expected to be minimal. Cancer Research UK notes that the other UK nations are still considering the recommendation.

BRCA2 is a gene that, when altered, raises the risk of several cancers. The NHS notes on its PSA test page that a faulty BRCA2 gene raises the risk of prostate cancer, which is why it is the one group currently singled out. Most men do not know whether they carry a BRCA variant. NHS genetic testing for BRCA variants follows set national criteria, so if you are unsure whether it applies to you, a GP or genetics service is the place to ask.

Why not screen all men?

This is the question many people ask. The committee's answer is that screening all men is more likely to cause more harm than good. The main reasons are:

• The PSA test is not accurate enough on its own. The NHS explains that a high PSA does not mean you have cancer, because PSA can rise for other reasons, such as an enlarged prostate. The test can also miss some cancers.
• Overdiagnosis. Some prostate cancers grow so slowly they would never cause harm. Finding them can lead to treatment a man never needed.
• Side effects of treatment. The committee's minutes point to the risk of incontinence and erectile dysfunction following unnecessary biopsy or treatment.

For men with a BRCA2 variant and a family history, the balance is different. The committee judged that, for this group, screening is more likely to do more good than harm. The equality impact assessment explains that other groups, such as men with BRCA1 variants or BRCA2 variants without a relevant family history, have a lower risk of clinically significant prostate cancer.

What about Black men and men with a family history?

Black men face a higher risk of prostate cancer. Prostate Cancer UK, quoted in the government's announcement, says Black men are twice as likely to get the disease and twice as likely to die from it. Many people were surprised they were not included.

The committee did not say screening would not help Black men. It said the evidence is uncertain. The equality impact assessment describes the evidence as limited and uncertain, with severe data gaps. The committee reached a similar view for men who have a family history but no BRCA2 variant.

To close that gap, the government is expanding the TRANSFORM trial, which is funded by the National Institute for Health and Care Research and Prostate Cancer UK. In its second stage, all eligible Black men will be invited to take part. Cancer Research UK says the trial compares fast MRI scans, genetic saliva tests and PSA blood tests, and looks at harms such as overdiagnosis.

The committee has also said its prostate screening model will stay open for a further three years, so that new high-quality evidence, especially on screening Black men, can be considered. Its formal next review is estimated for 2029 to 2030. So the current position may change.

How the targeted programme will work

According to the equality impact assessment, the pathway is:

1. a PSA blood test every 2 years;
2. if the PSA result is raised, a multiparametric MRI scan of the prostate;
3. if the MRI shows an area of concern, a biopsy;
4. if cancer is found, treatment or active surveillance.

This matches how prostate cancer is investigated more generally on the NHS. The NHS says that if you are referred to a specialist with possible prostate cancer, you will have an MRI scan, which gives a clearer view of the prostate and shows whether more tests are needed. If you have not had an MRI before, our guide to what to expect at an MRI scan explains what it is like.

What you can do now if you are worried

If you are not in the eligible group, you can still discuss a PSA test with a GP. The NHS says routine PSA testing is not offered, but men and anyone with a prostate can ask a GP about it. Your doctor will go through the benefits and risks so you can decide together.

It is worth asking if you:

• have symptoms such as needing to pee urgently or often, a weak flow, difficulty starting to pee or peeing during the night;
• have a close relative who had prostate cancer, or a family history of breast or ovarian cancer;
• are a Black man and would like to talk about your risk.

The NHS notes that these symptoms do not always mean prostate cancer and can also be caused by an enlarged prostate, but they should still be checked.

Where does private prostate MRI fit in?

A private prostate MRI is not the same as screening. In the NHS pathway, MRI is used after a raised PSA or a specialist assessment, to help decide whether a biopsy is needed. TRANSFORM is testing whether a quick MRI could play a role in screening in future, but that is not yet known.

Some people choose a private MRI after a GP has raised a concern, for example to reduce a wait. If you do, share the report with your GP or specialist so it can be acted on. Our guide to getting your scan images and report explains how. A normal MRI or PSA result is reassuring, but no test is perfect, and it does not rule out prostate cancer completely. Keep reporting any new or ongoing symptoms.

This article is general information, not medical advice. Please speak to your GP or the referring clinician about any symptoms or results. If your symptoms are urgent, call NHS 111, or 999 in an emergency.

Finding a private scan

You can compare regulated clinics offering a prostate MRI scan or other private MRI scans on FindScan. Each clinic lists its own price and confirms the final price with you. Some clinics accept self-referral for MRI and others ask for a referral from a GP or their own doctor, so check when you send an enquiry. The clinic will then contact you.